Association of HER2 expression in advanced urothelial carcinoma (aUC) and treatment outcomes with immune checkpoint inhibitors and enfortumab vedotin.

被引：0

作者：

Shipp, Chase Allain ^{[1
]}

Jindal, Tanya ^{[2
]}

Reyes, Kevin R. ^{[1
]}

Zhu, Xiaolin ^{[1
]}

Ding, Chien-Kuang Cornelia ^{[1
]}

Chan, Emily ^{[1
]}

Stohr, Bradley A. ^{[3
]}

Deshmukh, Prianka ^{[4
]}

Fitzgerald, Kelly N. ^{[1
]}

Kwon, Daniel ^{[2
]}

Bose, Rohit ^{[1
]}

Desai, Arpita ^{[1
]}

de Kouchkovsky, Ivan ^{[1
]}

Aggarwal, Rahul Raj ^{[1
]}

Small, Eric J. ^{[1
]}

Fong, Lawrence ^{[1
]}

Porten, Sima P. ^{[1
]}

Friedlander, Terence W. ^{[5
]}

Chou, Jonathan ^{[1
]}

Koshkin, Vadim S. ^{[1
]}

机构：

[1] Univ Calif San Francisco, San Francisco, CA USA

[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[3] Univ Calif San Francisco, Dept Pathol, San Francisco, CA USA

[4] Univ Southern Calif, Los Angeles, CA USA

[5] Univ Calif San Francisco, Med Ctr, San Francisco, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

613-213-2711-3371; 261-566-9718-9794; 283-183-138-12099; 3282-270-2686-7624; 261-492-3532-2370-7650-2700; 261-566-9263; 283-2627; 613-213-3369-5270-11573-3397; 8; 7; 6; 3; 2; 3224; 242; 1854; 1; 38092-22447; 38092-27449; 14; 5;

D O I：

10.1200/JCO.2024.42.4_suppl.599

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：599 / 599

页数：1

共 50 条

[1] Enfortumab vedotin (EV) outcomes with and without immediate prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial carcinoma (aUC).
Koshkin, Vadim S.
Henderson, Nicholas
Kilari, Deepak
Jindal, Tanya
Alhalabi, Omar
Freeman, Dory
Basu, Arnab
Barata, Pedro C.
Bilen, Mehmet Asim
Zakharia, Yousef
Emamekhoo, Hamid
Shah, Sumit
Milowsky, Matthew I.
Davis, Nancy B.
Gupta, Shilpa
Hoimes, Christopher J.
Grivas, Petros
Bellmunt, Joaquim
Campbell, Matthew T.
Alva, Ajjai Shivaram
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[2] Outcomes of enfortumab vedotin (EV) therapy in relation to prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial cancer (aUC).
Vlachou, Evangelia
Elias, Roy
Hahn, Noah M.
Mcconkey, David James
Johnson, Burles Avner
Hoffman-Censits, Jean H.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 570 - 570
[3] Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma
Mantia, Charlene M.
Sonpavde, Guru
[J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (05) : 449 - 455
[4] Biomarkers predictive of response to enfortumab vedotin (EV) treatment in advanced urothelial cancer (aUC).
Jindal, Tanya
Zhang, Li
Chou, Jonathan
Shui, David
Porten, Sima P.
Wong, Anthony C.
Chan, Emily
Stohr, Bradley A.
de Kouchkovsky, Ivan
Borno, Hala
Bose, Rohit
Kwon, Daniel H.
Desai, Arpita
Huang, Franklin W.
Aggarwal, Rahul Raj
Small, Eric Jay
Fong, Lawrence
Friedlander, Terence W.
Koshkin, Vadim S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[5] Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
Makrakis, Dimitrios
Talukder, Rafee
Lin, Genevieve Ihsiu
Diamantopoulos, Leonidas N.
Dawsey, Scott
Gupta, Shilpa
Carril-Ajuria, Lucia
Castellano, Daniel
de Kouchkovsky, Ivan
Koshkin, Vadim S.
Park, Joseph J.
Alva, Ajjai
Bilen, Mehmet A.
Stewart, Tyler F.
Mckay, Rana R.
Tripathi, Nishita
Agarwal, Neeraj
Vather-Wu, Naomi
Zakharia, Yousef
Morales-Barrera, Rafael
Devitt, Michael E.
Cortellini, Alessio
Fulgenzi, Claudia Angela Maria
Pinato, David J.
Nelson, Ariel
Hoimes, Christopher J.
Gupta, Kavita
Gartrell, Benjamin A.
Sankin, Alex
Tripathi, Abhishek
Zakopoulou, Roubini
Bamias, Aristotelis
Murgic, Jure
Frobe, Ana
Rodriguez-Vida, Alejo
Drakaki, Alexandra
Liu, Sandy
Lu, Eric
Kumar, Vivek
Di Lorenzo, Giuseppe
Joshi, Monika
Isaacsson-Velho, Pedro
Buznego, Lucia Alonso
Duran, Ignacio
Moses, Marcus
Jang, Albert
Barata, Pedro
Sonpavde, Guru
Yu, Evan Y.
Montgomery, Robert Bruce
[J]. CLINICAL GENITOURINARY CANCER, 2022, 20 (05) : E440 - E452
[6] Outcomes with immune checkpoint inhibitors (ICI) in patients (pts) with MTAP alterations (alt) in advanced urothelial carcinoma (aUC).
Talukder, Rafee
Bakaloudi, Dimitra Rafailia
Lin, Genevieve Ihsiu
Enright, Tom
Leary, Jacob Beck
Makrakis, Dimitrios
Tripathi, Nishita
Agarwal, Neeraj
Jindal, Tanya
Koshkin, Vadim S.
Brown, Jason R.
Johnson, Jeffrey
Zakharia, Yousef
Park, Joseph J.
Alva, Ajjai Shivaram
Barrera, Rafael Morales
Drakaki, Alexandra
Barata, Pedro C.
Khaki, Ali Raza
Grivas, Petros
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[7] Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin
Jindal, Tanya
Zhang, Li
Deshmukh, Prianka
Reyes, Kevin
Chan, Emily
Kumar, Vipul
Zhu, Xiaolin
Maldonado, Edward
Feng, Stephanie
Johnson, Michelle
Angelidakis, Austin
Kwon, Daniel
Desai, Arpita
Borno, Hala T.
Bose, Rohit
Wong, Anthony
Hong, Julian
Carroll, Peter
Meng, Maxwell
Porten, Sima
Aggarwal, Rahul
Small, Eric J.
Fong, Lawrence
Chou, Jonathan
Friedlander, Terence
de Kouchkovsky, Ivan
Koshkin, Vadim S.
[J]. CLINICAL GENITOURINARY CANCER, 2023, 21 (05) : e394 - e404
[8] Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
Kawahara, Takashi
Hasizume, Akihito
Uemura, Koichi
Yamaguchi, Katsuya
Ito, Hiroki
Takeshima, Teppei
Hasumi, Hisashi
Teranishi, Jun-ichi
Ousaka, Kimito
Makiyama, Kazuhide
Uemura, Hiroji
[J]. CANCERS, 2023, 15 (17)
[9] Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
Makrakis, Dimitrios
Bakaloudi, Dimitra Rafailia
Talukder, Rafee
Lin, Genevieve Ihsiu
Diamantopoulos, Leonidas N.
Jindal, Tanya
Vather-Wu, Naomi
Zakharia, Yousef
Tripathi, Nishita
Agarwal, Neeraj
Dawsey, Scott
Gupta, Shilpa
Lu, Eric
Drakaki, Alexandra
Liu, Sandy
Zakopoulou, Roubini
Bamias, Aristotelis
Fulgenzi, Claudia -Maria
Cortellini, Alessio
Pinato, David
Barata, Pedro
Grivas, Petros
Khaki, Ali Raza
Koshkin, Vadim S.
[J]. CLINICAL GENITOURINARY CANCER, 2023, 21 (02) : 286 - 294
[10] Association between sites of metastases (mets) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).
Makrakis, Dimitrios
Diamantopoulos, Leonidas Nikolaos
Koshkin, Vadim S.
Alva, Ajjai Shivaram
Bilen, Mehmet Asim
Stewart, Tyler Francis
Santos, Victor Sacristan
Jain, Jayanshu
Morales-Barrera, Rafael
Devitt, Michael E.
Carril-Ajuria, Lucia
Nelson, Ariel Ann
Sankin, Alexander
Zakopoulou, Roubini
Pinato, David James
Frobe, Ana
Joshi, Monika
Sonpavde, Guru
Grivas, Petros
Khaki, Ali Raza
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)

← 1 2 3 4 5 →